Elisabeth Turpin

Summary

Country: France

Publications

  1. ncbi Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers
    Jacqueline Lehmann-Che
    INSERM CNRS University Paris 7, UMR 944 7212, Hopital Saint Louis, 1, Av Claude Vellefaux, 75 475 Paris Cedex 10, France
    Oncologist 15:246-52. 2010

Collaborators

  • Jacqueline Lehmann-Che
  • Lajos Pusztai
  • Louis François Plassa
  • Fabrice Andre
  • Christos Sotiriou
  • Martine Piccart
  • Christine Desmedt
  • Michel Marty
  • Sylvie Giacchetti
  • Chafika Mazouni
  • Hugues De The
  • Philippe Bertheau
  • W Fraser Symmans
  • Marc Espie

Detail Information

Publications1

  1. ncbi Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers
    Jacqueline Lehmann-Che
    INSERM CNRS University Paris 7, UMR 944 7212, Hopital Saint Louis, 1, Av Claude Vellefaux, 75 475 Paris Cedex 10, France
    Oncologist 15:246-52. 2010
    ..The latter allowed very high levels of pCR in triple-negative tumors. Thus, our data strongly suggest that cyclophosphamide dose intensification in ER(-) p53-mutated breast cancer patients could significantly improve their response...